Evidence Hub

Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience

Carbone PP

Breast cancer research and treatment, 1983

Abstract

Adjuvant therapy trials in breast cancer have grown steadily more complex since 1971, when the first long-term adjuvant trial in the United States was initiated. From L-PAM alone or in combination with a few other cytotoxic agents, ECOG protocols have expanded to consider different multidrug combinations with tamoxifen and other endocrine agents, administered for various lengths of time, sometimes alternating between two combinations. Nevertheless, we are still in the gestational stages of adjuvant studies, with many critical questions yet to be answered.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free